Precigen, Inc. Hits Day Low of $3.88 Amid Price Pressure

Precigen, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, experienced significant volatility on November 20, 2025, with its stock price declining by 19.59%. The stock reached an intraday low of USD 3.88, reflecting a challenging trading environment.
Over the past day, Precigen's performance starkly contrasted with the S&P 500, which saw a modest gain of 0.38%. In the broader context, the company's one-week performance showed a slight decline of 2.99%, while its one-month performance was down by 2.5%. However, looking at a longer timeframe, Precigen has demonstrated remarkable growth over the past year, with a staggering increase of 390.2%, significantly outpacing the S&P 500's 12.26% gain.

Despite this impressive annual performance, Precigen faces underlying financial challenges, including operating losses and a weak long-term growth trajectory, as evidenced by a net sales decline of 46.64% over the past five years. The company's debt-to-equity ratio stands at a high 926.05%, indicating potential financial strain. As Precigen navigates these complexities, its market position remains a focal point for stakeholders.